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Over the past decade heart ransplantation has evolved from 
a rarely performed experimental procedure to an accepted 
therapy for end-stage heart disease. Despite the escalation i  
the number of procedures and the progressive improvement 
in postoperative outcome as described by Task Force I, two 
formidable obstacles continue to challenge the success of 
heart ransplantation. 
Contemporary immunosuppressive strategies have re- 
duced the incidence of acute rejection but have severe 
limitations. These include lack of specificity, inability to 
reduce the risk of cardiac allograft vasculopathy (the major 
factor limiting long-term recipient survival), significant tox- 
icity and an increased risk of opportunistic infections and 
malignancy. 
The understanding of the immune respouse at increas- 
ingly fundamental levels and the ability to combine data from 
in vitro assays of immune function with information from in 
vivo models of organ transplantation and autoimmune dis- 
ease have enabled rapid advances in the discovery and 
development of new immunosuppressive modalities. These 
include I) the discovery of new molecules that affect he 
response of immune cells to antigenic stimuli by inhibiting 
either cytokine synthesis, the action of cytokines and growth 
factors, deoxyribonucleic acid (DNA) synthesis or cell mat- 
uration; 2) the introduction of less toxic and more selective 
monoclonal ntibodies targeting cell subsets, adhesion mol- 
ecules or cytokines mediating the rejection process; 3) the 
use of therapeutic irradiation of the immune system; 4) the 
use of apheresis procedures; 5) the development of gene 
manipulation strategies directed at alteration or suppression 
of alloantigens. 
Although these advances will improve the outcome of 
heart ransplantation, none of them is a solution for the most 
pressing problem facing organ transplantation: the critical 
shortage of domor organs. Because the pool of potential 
candidates continues to expand while donor organs remain 
critically scarce, the discrepancy between the number of 
patients who would benefit from heart ransplantation a d 
the number of patients who actually receive a transpianr 
continues to increase at an alarming rate. It is estimated tha? 
as many as 30% of patients awaiting heart rausplantation die
before a suitable donor organ becomes available. The severe 
shortage of donor organs emphasizes the crucial need for 
identifying alternatives toallotransplantation. Potential so- 
lutions include 1) xenotransplantation, 2) the application of
transformed skeletal muscle, and 3) mechanical ssist and 
replacement devices. 
This report will Laddress both future developments in
immunosuppression thatmay help optimize the use of scarce 
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Agent 
~~bibits action of IL-2 
Phase II clinical w&i 
Animal studies 
Mycophenolate mofetil 
(RS-61443) (9-11) 
Inhibits purine biosynthesis Phase II clinical trials 
zoribine (bredinin) (IZ,P3) 
equinar sodium (14.15) 
ibits purine biosynthesis 
ibits oyrimidine biosynthesis 
base 11 clinical trials 
Phase II c[inical trials 
IS-Deoxyspergualin (16.17) ~~k~o~~, may inhibit interferon 
IL-2 = interleukind. 
g&ion are shown in Table 1. In animal models ai1 these 
have been shown to prolong allograft survival and, in 
cases, to reverse ongoing allograft rejection. 
ct.5 associated wit 
have been observe 
mental and clinical investigation are s 
Because clinically avai 
significant toxicity and I 
years efforts have been directed toward the deve~o~rne~~ of 
less toxic and more selective forms. The types and immu- 
nologic target of some of these moooc:o~a~ ntibodies are 
sh 
3 (ET). The 
TCR/CXM complex is a molecular structure present on the 
T&k 2, Adverse EBer!s of New Immunosuppressive Drugs 
to sMccessf~~~y reverse 
ecessary for ~~~~a~ e 
revent he pro~~fera~~o~ of alloreactive T cells 
rleukk 2 receptor rno~oc~o~a~ anti- 
-1 and anti-TAC) have undergone 
ase II clinical trials in kidney and liver transplant recipi- 
ts. The ability of these antibodies to prevent rejection 
appears to be similar to that of either OKT3 or a~~i~hymo- 
cyte globulin. _~~i~-i~~er~e~ki~-2 
tive in reversing ongoing rejection. 
. 
The synergsm recently oerno~s~ra~ed iii VitiO betwizen 
Cjdospoiine Mycophenolate Brequinar 
Analogues FWit6 Rapamycin Mofelil Mizoribine Sodium Deoxyspergualin 
Nephroioxicity f + + + 
Hypertension t - - 
tiepatoroxiciiy -i + t - t - + 
Gastrointestinal complications f t t t 
Glucose intolerance i + - _. - 
Myelosuppression - f t t 
Neurotoxicity t- - 
Angionecrosis .- - f 
Mucositis __ - + 
Angioneurotic edema - - _. + 
Skin rash .- - - + 
- 
- = absent; + = present. 
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Table 3. New Monoclonal Antibodies and Their Targets - -- 
Tareet Mo~c~clonal Antibody 
T cell receptor Anti-alpha/beta TCR 
T cell subset Anii-CD4 
Lymphokine receptor Anti-IL-2 R 
Lymphokine Anti-TNF alpha 
Adhesion tiaand Anti-ICAM,. 
TCR = T cell receptor; IL-2 R = interleukin-2 receptor; TNF = tumor 
necrosis factor: ICAM-: = intercellular dhesion molecule-l. 
3383. I (anti-interleukin-2 receptor alpha-2 chain) and TU27 
(an interleukin-2 receptor beta-chain monoclonal ntibody) 
may have useful clinical applications (32). 
Monoclonal antibodies directed agcrinst costimdatov 
molecules. In addition to the TCR-CD3 complex, other 
molecules (costimulatory) that identified on T ceils play 
important roles in cell to cell interactios: and T cell activa- 
tion. CD4, an accessory moler;ule present on helper-inducer 
T cells, binds to class II human leukocyte antigen (HLA) 
antigens and increases the overall avidity of the interaction 
between T ceils and target cells (33). In many rodent studies 
anti-CD4 monoclonal ntibodies, by functionally inactivat- 
ing CD4+ T cells, abolish help for antibody responses, 
inhibit cell-mediated alloimmunity and prolong aliograft sur- 
vival. In larger animal models only the combined use of a T 
cell coating anti-CD4 monoclonal ntibody with a depleting 
anti-T cell monoclonal ntibody has shown therapeutic effi- 
cacy (34-37). 
QKT4A, a murine anti-human CD4 monoclonat ntibo&i, 
has significantly prolonged primate renal allograft surviva1. 
Further studies of optimal OKT4A doses are needed to 
establish its efficacy (38). 
The interaction between CD28 and its ligand on antigen 
presenting cells, B7, is essential for T cell activation. A
recently developed molecule, CTL4AIg. which binds to 97 
and prevents its interaction with CD28, may become a
clinically useful tool for the prevention and treatment of
aliografl rejection (39). 
Monoclonal ies reacting with adhesion molecules 
and lymphokines. Because tumor necrosis factor plays a 
central role in immune activation by regulating production of
interferon, interleukin-3 and interleukind, the use of anti- 
tumor necrosis factor monoclonal ntibodies early in the 
immune response may decrease interieukin-induced MLA 
antigen expression on ceil membranes (40,41). Because 
interleukin-2 secretion isnot inhibited by anti-tumor necro- 
sis factor monoclonal ntibodies, a combination fanti-CD3 
and anti-tumor necrosis factor monoclonal ntibodies with 
cY be required for clinical efficacy (42). 
tibadies directed at the ligand OF adhesion 
molecules. The intercellular dhesion molecule-l (ICAM-l), 
a ubiquitous ceil surface molecule, is a iigand for the 
CD1 i/CD18 complex leukocyte function associated 
molecule-1 (LFA-1). R6.5, a murine IgG2a monocional n- 
ti!%&f directed against ICAM-1, slightly prolonged primate 
renal aliograft survival when used prophylactically and im- 
proved aliograft unction in 75% of recipients when used as 
a rescue therapy (43). 
The combination of anti-1CAM-i and anti-L 
monocional ntibodies can produce indefinke cardiac al- 
lograft survival in fully MHC-incompatible murine strains 
(44). Anti-ICAM- monoclonal ntibodies may also reduce 
oxygen radical reperfusion damage by blocking binding a 
neutiophils to the ICAM- on vascular endothelial ceils. 
onoclnnall nti 
cells. Preoperative d  
plement-fixing monocional ntibody 
pancreas allograft su 
patients with a renal allograft, rejection ra 
recipients of kidneys flushed with anti- 
common antigen) monoclonal ntibodies than in a control 
umanized rno~~~ona~ an urine monoclonal 
antibody-induced T ceil activation corre 
typic hierarchy (IgG2a > Ig 
relative ability of the individual isotypes to bind human 
monocyte Fe receptors, whereas cytolytic activity is a 
function of the epitope specificity of the monocional nti- 
body. Thus, hybrid human-mouse monoclonai antibodies 
have been constructed that have human immunoglobuiin 
structure xcept for the limited complementarity determin- 
ing regions that confer epitope specificity to the monoclonal 
antibody (48). 
Implications. Data from animal studies and pilot clinical 
trials indicate that monoclonal ntibodies i;rGvidc the oppor- 
tunity to selectively perturb the immune system for a limited 
period of time during the development of ailoreactive im- 
mune responses (49). The ultimate goal of monoclonai nti- 
bodies in clinical transplantation should remain the introduc- 
tion of short-term treatment protocols leading to specific 
suppression of donor-specific alloreactivity. The growing 
understanding of structure and function of costimulatory 
molecules on T cells and of their targets may permit he 
development of combination immunosuppressive regimens 
that will simultaneously block multiple accessory molecules 
essential for immune ceils activation and interaction with 
their targets. 
Strategies 
Totad Lymphoid Irradiation 
Total ymphoid irradiation isthe fractionated delivery of 
a widely variable total range of radiation (up to 2,000 rads) to 
lymphatic tissues using standard inverted Y-mantle fields. 
This treatment induces changes in immune regulation man- 
ifested by an initial period of nonspecific, broad spectrum 
immunosuppression followed in some cases by evolution to 
specific aiiograft tolerance (50) and has been used in organ 
transplantation and autoimml;ne diseases (51). The period of 
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ability prechrde use of total 
ditioning for heart transpla 
&at one of the patients wh 
waited for suitable organs (53). Total 
has been successfully used in the treat 
include its use in the ~eri-transplant per 
rine, FM06 or monoclonal ntibodies; combined treatment 
with immunosuppressive ag nts or mo~oc~ona~ anti 
may permit lower total amounts of radiat~Qn. The dra 
to such use will be the length of time to response (probably 
weeks), and the high frequency of cardiac allograft rej 
currently experienced in the early posttra~s~~a~t peri 
iikely continue to occur Because the use of total ympboi 
irradiation Yl/ili induce a t>eriod ofgeneral immune unrespon- 
siveness immediatejy after grafting, 2 similar spectrum of 
infections hould be expected. These may be even more 
frequent and serious because neutropenia is a major limiting 
factor in many patients undergoing standard total ymphoid 
irradiation. Side effects may become less frequent as more 
experience is gained with lower dosage and co~~omit2~~ use 
of myelopoietic growth factors. 
The current regimen of fractionated weekly dosage over 
at least 5 weeks implies that total lymphoid irradiation 
cannot be used in urgent or “rescue” situations. Because it
may be 2 potent suppressant of alloantibody production, it
would seem to be 2 promising treatment modality for hu- 
moral rejection. Its effects on allograft vasculopathy are 
unknown. When donor bone marrow cells are administered 
in conjunction with total lymphoid irradiation, rat heart 
allograft survival is markedly prolonged (56). Continued 
improvement in bone marrow transplantation techniques 
may allow concomitant donor marrow transplantation with 
total ymphoid irradiation 2nd creation of the chimeric state 
that would obviate the need for long term immunosuppres- 
sive drug therapy. 
Apheresis Procedures 
Continuing improvements in fluid and cell separation 
technology have fostered creative uses of apheresis nclin- 
cytokines and soluble 
ay allow successful 
heart r2~s~~antatio~ may abrogate tbe rapid reappearance 
of a~~oa~tibodies and ubseq.uent rejection (5). 2) patients 
who require blood product replacement during ical 
“bridging” procedures can become HEA sensitized. Anti- 
HLA antibody can be maintained atlow levels by intermit- 
tent therapeuti? or c ..asma exchange until a suitable donor is 
available (57). 3) There is anecdotal evidence that vascular 
rejection can be reversed with therapeutic plasma exchange. 
Bf the importance ofhumorai nt~~ody-~~~d~a~~d i-ejection 2s 
2 significant pathologic component ofcardiac a~~og~aft loss is 
confirmed, there will be increased use of therapeutic 
tein A immunoadso 
coccal cell wall extract that specifically binds the Fc com- 
ponent of IgG antibodies. Although there is interest in this 
type of strategy to reduce pre-transplantation anti-I&A 
antibodies in prospective r cipients (99, the future use of 
global antibody ads ion techniques in transplantation 
appears limited in vie f the rapid advances being made in 
the production of specific olumn adsorbents hat can be 
individualized to 2 patient’s specific. HLA sensitization pat- 
tern. 
in understanding the structure and function 
antigens and parallel advances in recornb~~~a~t te 
that can produce them in significant 
the availability for coupling specific 
priate biologically inert substrates and using the speci 
‘“immunofilter” as the second step in dual filtration plasma 
separation. Such technology will provide an opportblnity to 
reduce antibody levels in sensitized patients to a level where 
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the need for a prospective crossmatch is obviated. Several 
HLA-linked immunoadsorbents are already available. 
Photopheresis 
Photopheresis i  a new treatment modality hat exploits 
ex vivo ultraviolet-A (320 to 460 nm) light activation of
mononuclear cells obtained by leukopheresis from a patient 
after ingestion ofS-methoxypsoralen. Th  photomodulated 
mononuclear cells are then reinfused. Although t e precise 
mechanisms of photopheresis remains obscure, cell surface 
photo-modulation by ultraviolet-A light-activated, mono- 
nuclear cell-bound psoralen appears toenhance suppressor 
mechanisms by altering antigen presenting mechanisms or 
cytokine ligands. Photopheresis ha been successfully used 
in the reversal of moderate h art ransplant rejection not 
complicated by hemodynamic compromise (59), and recal- 
citrant cardiac rejection (60). Although the fundamental 
concepts of photopheresis may hold future promise inclin- 
ical organ transplantation, the current need for relatively 
cumbersome cell collection techniques, x viva cell manip- 
ulations and c)st may relegate i  to a passing note of interest 
as newer methods ofdelivering ultraviolet light o effector 
mechanisms aredeveloped. 
The use of ultraviolet-B (298 to 320 nm) light for allograft 
induction tolerance would seem to hold future promise but 
there are significant hurdles to overcome before its use. 
Ultraviolet B light, with or without concomitant immuno- 
suppressive th rapy, isstrongly tolerogenic in a wide range 
of species (61). The recent identification of urocanic a id and 
ICAM downregulation as potential mediators of ultravio- 
let-B light alteration f host effector cells and donor alloan- 
tigenic determinants should prompt further intense investi- 
gation. 
Gene ~unip~~ations in art Tra~spfuntation 
The barriers for clinical usefulness of gene manipulation 
techniques in heart ransplantation areformidable. The 
process would have to be highly efficient, rapid (occurring 
between donor explantation a d recipient reimplantation) 
and effective in cold ischemic conditions, and gene xpres- 
sion would then have to be stable and uniform throughout 
the coronary bed. Genetic alteration of an intact donor 
before xplantation would probably raise thical issues. 
The initial strategy of gene transfer inheart transplanta- 
tion will presumably e directed atalteration r suppression 
of donor HLA and non-HLA-specific coronary bed endo- 
cardial ntigens. Several diverse approaches to genetic ma- 
nipulation are being pursued. Successful plasmid transfer of
gene xpression to skeletal muscle can be done. Stable 
expression of the nonmammalian genes occurred after direct 
gene injection i to the extravascular space of a rat cardiac 
isograft but was limited in time and spatially restricted to the 
injection site (62,63). 
Thus, direct gene transfer to donor organs, an exciting 
concept that may have relatively rapid ~~pI~catio~ in cell 
transplantation, may require several years of invest~~~tio~ 
before itbecomes u eful in heart t~nsplantatio~. Transgenic 
construction f human I-ILA or non- 
xenografts and creation of YLA-deficient xenoorga~s by 
fetal gene deletion to prevent effector cell recognition, are 
techniques that hold promise. Finally, mas 
bound peptides orreplacing them with counterfeit recipient 
peptides topromote xeno or allo tolerance is becoming 
feasible. 
the developments outlined above, none of them will address 
the most pressing problem facing all transplant centers 
today, namely the severe shortage of donor organs. A 
potential resolution may lie in one of the three areas dis- 
cussed below: 1) xenotra~s~~a~tatio~~ 2) the application f 
transformed skeletal muscle, and 3) mechanical a.ssist and 
replacement devices. 
Cardiac Xe~otransp~a~tat~~~ 
The entire field of xenotransplantation bas recently been 
comprehensively reviewed (64). 
uctiou. Xenotrunspluntation refers to the trans- 
plantation f organs or tissues from an animal of one species 
into an animal of another species With regard to ~~rn~~ 
beings, it clearly refers to the use of a nonhuman donor. The 
terms concordant and discordant xenografting are used 
frequently torefer espectively to transplantation between 
closely related animal species (e.g., baboon to human) and 
between distantly related animal species (pig to human). 
Histopathologically, rejection of a xenograft may be 
1) cellular, 2) vascular (antibody-mediated, humoral), or 
3) mixed. Vascular rejection may be hyperucute (in that it 
occurs within minutes or a few hours after transplantation) 
but may be more delayed and can even occur some days 
after transplantation. 
Several logistic and ethical problems need to be ad- 
dressed with regard to concordant xenografting  humans. 
There is currently an inadequate number of the larger 
nonhuman primates (e.g., chimpanzees), and the size of 
other nonhuman primates (e.g., baboons) would be inade- 
quate to allow orthotopic heart transplantation in adults. Itis 
possible that a role for the nonhuman primate may be found 
in heart ransplantation for neonates and infants, but the 
controversy that such use is likely to engender may prohibit 
its development. 
Our attention must probably, therefore, be directed to- 
ward ascertaining themost suitable discordant animal donor 
for humans, and for several reasons, the pig has been so 
identified. It is 1) available inlarge numbers, 2)inexpensive 
to breed and maintain, 3)of a suitable size for the smallest or
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ity of elonor organs would have on hedth care ecmomics i  
clearly immense. furthermore, i ies where brain 
death is not yet recognized or in 
not yet been educated su 
do~at~Q~, it seems likely 
y. In concordant xenografti 
usually no or very low detectable l vels Qfa~t~-do~or species 
(xenoreactive) antibody in the host at 
tation. Rejection may be cellular a 
sequence of even 
cular or of a mixe 
development of both cellular and ascular ejection may 
differ significantly from those docu nted in allografts. The 
relative proportion of cases where cellular (rather than 
vascular) ejection piit resuh varies depending on the two 
animal species involved dnd possibly on the organ trans- 
planted. 
In discordanr xenografting, rejection is uniformly vascu- 
lar and generally hyperacute. There is increasing evidence 
that it is entirely or largely a result of antibody-med~aFed 
complement activation through the classical pathway. 
~~r~e~t status. CIKYZ~. Although there have been at- 
tempts at both clinical concordant and d!scordant organ 
xenografting, our knowledge in this field does not warrant 
clinical attempts at the present ime, with the possible 
exception of cautious clinical trials at centers with a special 
research interest and expertise in this field. With regard to 
the heart, there have been five transplants u ing nonhuman 
primates, the most recent being in 1984, and four transplants 
using the pig or sheep as donors for humans, the most recent 
being reported in 1992 (65). The maximal survival time of a 
concordant graft has been 20 days and that of a discordant 
graft has been 24 h. 
Experimental. Some r ccc;;: progress has been made in 
extending concordant heart survival utilizing either a com- 
bination of total lymphoid irradiation and pharmacologic 
immunosuppression or high dose immunosuppressive th r- 
apy alone (66,67). Whether such regimens will be well 
tolerated by debilitated cardiac patients remains uncertain, 
but clearly such high dose immunosuppressive programs are 
likely to be associated with a higher incidence of infection 
and new malignancy than is associated with allografting at
the present time. 
The problem of hyperacute vascular ejection, particu- 
larly of a discordant xenograft, has to date proved an 
to those currently available. 
The incidence and rapidity of onset of graft atherosclero- 
sis remain ~~k~ow~ in both concordant and discordant 
experimental models. Similarly, it remains uncertain 
whether retra~s~~a~tati~~ wi  
fully carried out in the event of failure of a xenograft. There 
is conflicting evidence as to whether cross-reactive antibod- 
ies will develop that might canse arly failure of the subse- 
quent allograft . 
Application of ~ra~s~or~e~ Skeletal 
The use of skeletai muscle to provide aux- 
iliary pumping capacity to a patient with left ventricular 
dysfunction as an alternative to cardiac transplantaticn is 
theoretically attractive for seve.-al reasons. Each patient 
could serve as his or her own donor of skeletal muscle, 
obviating the need for immunosuppression. Also, patients 
with concomitant diseases such as cancer or renai nsuffi- 
ciency, or advanced age, ordinariiy not eligible for heart 
transpirntation, could undergo skeletal muscle surgery. 
Coordinated and repetitive contraction of the skeletal 
muscle is necessary for cardiac aogmentatio~. Normally, 
skeletal muscle subjected torepetitive electrical stim~~atio~~ 
over a short period of time fatigues rapidl 
contraction, degeneration a d fibrosis of 
sues. However, skeletal muscle has the capacity to undergo 
profound changes in morphologic, biochemical nd physio- 
logical properties in reqnse to chronic electrical stimula- 
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tion over a 6 to 8 week period. This principle, called skeletal 
muscle plasticity, results in a transformed skeletal muscle 
that is fatigue resistant and is responsible for the develop 
ment of the cardiomyoplasty procedure and related ap- 
proaches (70,71). 
Techniques. The surgical pproach involves mobilizing a 
large skeletal muscle with vascular and nervous SUPPLY 
intact. The position of the muscle is then transposed within 
the thoracic avity either to wrap around the heart or to 
construct a skeletal muscle “ventricle” around a portion of 
the aorta. The most commonly used muscle has been the 
latissimus dorsi muscle, primarily because of the anatomy of
its neurovascular supply, ease of transition into the chest 
and relatively large size. Then, a cardiomyostimulator 
(Medtronic), which has the capacity to individually transmit 
by transcutaneous telemetry the pulse-train duration, pulse 
frequency, pulse width. voltage and stimulation timing from 
myocardial systole, is positioned to transform the skeletal 
muscle over 6 to 12 weeks. 
Review of experience.. The first case of dynamic ardio- 
myoplasty was reported by Carpentier and Chachques in
1987 (72). Subsequently, asof April 30. 1991, 14 centers 
worldwide had entered atotal of 112 patients into the Phase 
I study sponsored by Medtronic Inc., which began enroll- 
ment in July of 1985. The latissimus dorsi muscle flap has 
been used to date in several ways to support cardiac func- 
tion: I) It is wrapped around either the atrial or the ventric- 
ular chambers tosupport contractile dysfunction secondary 
to congenital cardiac defects or surgery to correct such 
defects. 2) It is used as a substitute for myocardial wall 
surgically removed because ofmalignancy oraneurysm. 3)It 
is wrapped around the heart o support and augment function 
of the failing left ventricle secondary to ischemic heart 
disease or other forms of cardiomyopathy. Phase II clinical 
trials began in 1991; the U. S. Food and Drug Administration 
extended the number of North American clinical investig+ 
Rional centers from one to six for this phasr. 
In October 1991, an average implant experience of I4 
months (range 0to 46) had been accumulated onthe cohort 
of 112 patients in the Phase I trial. The patients, predomi- 
nantly male (88%) with an average age of 52 years, had an 
average l ft ventricular ejection fraction of 18.3%; 40 pa- 
tients (36%) were in New York Heart Association functional 
class 1V and 70 patients (62%) were in class III preopera- 
tively. The most common etiology for heart failure was 
ischemic ardiomyopathy (56%) and idiopathic dilated car- 
diomyopathy (37%). Seven patients (6%) had Chagas’ dis- 
ease. Concomitant surgical procedures performed in addi- 
tion to cardiomyoplasty, primarily coronary artery bypass 
graftir~g and aneurysmectomy, were undertaken i 23% of 
Patients. Early death, before hospital discharge, occurred in 
25 patients (22X), with a higher risk for early postoperative 
death in patients in preoperative functional class IV (37.5% 
early deaths) than in patients in class III (13.9% early 
deaths). An additional 22 patients died after the initial 
hospital discharge and were classified in the group with late 
death. Of the patients who survived the initial hospital stay, 
85% had an average improvement i  functional class by i .6 
class. Left ventricular ejection fraction after tra~sp~a~tatio~ 
showed a small but statistically insignificant increase over 
preoperative alues (73,74). Ongoing hemodynamic studies 
will further eliicidate the potential benefits of the procedure 
or cardiac performance. 
Theoretic considerations. The mechanisms by which the 
skeletal muscle wrap improves the functional ability of a 
patient with chronic heart failure are complex and may 
include an augmentation f left ventricular systolic function 
primarily through the action of the sy~c~r~~~~zed s 
muscle contraction, a conservation of rnyoca~~~~a~ energy
eserves, enhanced volume traoslocation rather than the 
increased potential for pressure generation, ormalization f 
the afterload mismatch that characterizes nd-stage dilated 
cardiomyopathy, improved ventricular in’ traction or pre- 
vention of ventricular dilation. 
Selection of candidates. The patient best suited to benefit 
from cardiomyoplasty has not been described and the ex- 
pected benefit from the procedure has not been well estab- 
lished. There seems to be a general consensus that dynamic 
cardiomyoplasty poses a greater risk for patients in preop- 
erative functiona! class IV, primarily because there is not 
sufficient time for transformation f the skeletal muscle in 
these very ill patients. Some patients who have undergone 
cardiomyoplasty have subsequently undergone transplanta- 
tion (75). 
Conclusions. Until further data are accumulated. cardio- 
myoplasty remains an iravestigational approacla to severe 
chrorric heart failure. 
Ventrichr Assist Devices 
Ventricular assist devices, excluding intraaortic balloon 
pumps, can be divided into two categories based on their 
intended use for short- or long-term circulatory support. 
Short-term devices have been most commonly employed to 
provide nonpulsatile univentricular o biventricular assis- 
tance for patients who cannot be separated from cardiopul- 
monary bypass after reparative cardiac surgery. Although 
long-term survival rates for these patients have been disap- 
pointing, particularly inthe setting of perioperative myocar- 
dial infarction, a significant subset of patients may benefit 
from this technology (76). Fortunately, the need for postcar- 
diotomy support remains mall and is diminishing because of
improvements in cardiac surgiz?J techniques. 
Short-term assist devices may also have a role in patients 
with rapidly progressive heart failure syndromes. Although 
most patients with this presentation have irreversible myo- 
cardial impairment, occasional dramatic improvement of
myocardial function can occur (77). More widespread use of 
circulatory support devices in the setting of acute myocar- 
dial failure remains limited by the lack of availability of 
long-term cardiac replacement therapy. 
More relevant to the area of heart transplantation are 
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discussion will focus on ~~~s~~~~e d 
alternatives to he 
ecause these devices are 
to tra~s~la~tatio~ because t 
f donor hearts. Although the 
individual patients who receive the device before transplan- 
tation now virtually equals that of patients who undergo 
transplantation without this device, the use of these bridging 
devices has negligible epidemiologic impact on the treat 
of end-stage heart disease whereas it may increase costs. 
Countera~g~me~ts to these concerns are that, as advocates 
for their patients, transplant physicians and surgeons must 
be free to utilize any technology available that may be 
beneficial for an individual patie t. and that budging allows 
the development and evaiuation ofdevices that can eventu- 
ally be used as long-term alternatives totraas~la~tatio~. 
Patient management conce s after imp~a~tatio~~ of pul-
satile ventricular assist device include maintenance of right 
ventricular nd noncardiac organ function and prevention of
infections and thromboembolism. Devices with smooth in- 
es and mechanical valves require systemic anti- 
coagulation, whereas those with rough surfaces and porcine 
valves have been employed for long periods without antico- 
agulation. 
In contrast o heart transplantation, management of a 
pulsatile left ventricular assist device does not require the 
use of immunosuppressive drugs. It is not known how the 
long-term use of these devices will affect he compensatory 
responses associated with chronic congestive heart failure, 
but this question will certainly be an area for important 
future investigation. 
To date, both the Novacor and the Therm0 Cardiosys- 
terns Inc. (TCIj devices have been evaluated inmuhicenter 
clinical trials. The Novacor device has been implanted in132 
patients with a maximal implantation time of 370 days 
(Partner PM, personal communication, December 1992). 
Seventy-nine patients (60%) subsequently received atrans- 
plant, and 70 (89%) of these patients urvived the transplant 
hospitaliiation. Although quantitative r ports of cerebral 
e per ~a~~e~t-year of observation. Long- 
~/a~a~~ use has not been required for this 
unacceptable ~~fect~o~ 
s~~staatia~~y as use of 
spread. In addition, these high c 
the alternative of prolonged hos 
patients for whom the device i 
resuits of muiticenter clinical triais of left ventricular ssist 
apid advances indevice design will soon 
ating these devices as alternatives rather 
than mere bridges to heart ransplantation. 
The preceding summary has atkmpted to outhne l.) the 
rtrivaorer in imwlllm~mnai~ll~*jn~ +RQ+ b*r ;mm~11*rkn +ro,nr . . . ..I.._ ” ..a ..‘~“.Y‘I”,,L”UUIULI ” LIILa, "J lrlryrvrrll~ LIUIID- 
plantation outcome, will contribute to optimal use of scarce 
donor organs; and 2) the d~~ve~op~~e~t of alternative surgical 
approaches that may decrease, if not obviate, the need for 
human heart allografts. 
The growing understanding of alloimmune r sponses may 
help elucidate the mechanisms of novel immunomodu~atory 
strategies, atTording insighs into new single 01 combination 
regimens. These insights are currently elusive because ofthe 
and techniques, the 
the variety of exper- 
iver:,e species. These 
possibilities ado a bewildering level 
usual therapeutic problems ofselectin? 
routes and schedules ofadministrati~ 
of in vitro assays have been used as indexes of alloreactivity, 
they show only inconsistent correlations with clinical 
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events. Only stringently controlled in vivo studies in ro- 
Jcnts, large animal models and humans will determine which 
agents or procedures represent real improvements over 
conventional therapy. 
The results of preclinical transplantation models and 
initial clinical trials suggest that immunosuppression EOh 
transplant patients i  likely to evolve into various combina- 
tion regimens. it appears now that there will be a choice 
between cyclosporine and FK506 as baseline immunosup- 
pression, because clinical experience has shown that these 
two drugs cause excessive nephrotoxicity when used in 
combination. Ideally, the combination of additional new 
agents will enable the doses of cyclosporine and FK506 to be 
lowered to levels that are nonnephrotoxic and at the same 
time minimize or completely eliminate the need for corticos- 
teroids and anti-T-cell antibody therapy. 
The diverse mechanisms of immunosuppressive action of 
the new drugs under investigation certainly o&r the hope for 
creative and effective strategies for the control of many 
forms of graft rejection in the very near future. As the 
precise molecular mechanisms of immunosuppression and 
toxicity of these new drugs become known, rational drug 
design shouid enable analogues with greater therapeutic 
indices to be developed. 
The future utility of immunosuppressive drugs, monoclo- 
nal antibodies and techniques will also depend upon their 
cacy in preventing and treating allograft vasculopathy and 
in inducing astate of tolerance that would obviate the need 
for Iong-term ~mr~u~osu~pressive drug therapy. 
The future appcication f xenotransplantation depends on 
a solution to the controversies that he use of animals for this 
purpose is likely to engender and the discovery of methods 
capable of overcoming hyperacute vascular and cellular 
xenotransplant rejection, 
In t6e foreseeable future, cardiomyop~asty will remain an 
invest~atio~a~ a~ r~ac~ to the treatment ofend-stage heart 
disease because the optimal candidates for cardiomyoplasty 
and the expected benefit from the procedure remain to be 
established. 
The main focus of investigation in the area of mechanical 
ventricular ssistance should be the development of devices 
for long term use. Technical, regulatory and financial con- 
straints have precluded the rapid development of these 
devices. However, the encouraging results of preliminary 
clinical trials as well as rapid advances indevice design may 
soon lead to the evaluation of ventricular assist devices as 
alternatives rather than mere bridges to heart ransplantation. 
To investigate any of these xciting potential therapeuttc 
advances, a framework must be developed for meaningful, 
multicenter cooperative trials. Issues that must be resolved 
before outside funding agengies will feel comfortable in
approaching the cardiac transplant community are: 
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1. A well established multicenter cooperation that will 
ensure availability of patie:nts. 
2. Ability to agree and adhere to a) i~c~~s~o~ an 
sion criteria, and b) protocol compliance 
3. definition of appropriate background therapy against 
which new modaiities wiii be tested. 
4. Definition of response criteria and vali oints 
other than survival. 
The future of heart ra~s~~a~tat~~~ depe 
ment to cooperation within individual ins 
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